MacroGenics, Inc. (NASDAQ:MGNX) is set to announce its earnings results after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. During the same period last year, the business earned $1.12 earnings per share. The company’s revenue for the quarter was down 97.9% on a year-over-year basis. On average, analysts expect MacroGenics to post $-4.26 EPS for the current fiscal year and $-3.94 EPS for the next fiscal year.

MacroGenics, Inc. (NASDAQ:MGNX) opened at 16.84 on Tuesday. MacroGenics, Inc. has a 52 week low of $14.36 and a 52 week high of $31.85. The stock’s market capitalization is $619.68 million. The stock’s 50 day moving average is $17.69 and its 200-day moving average is $18.14.

A number of research analysts recently commented on the company. BidaskClub downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. Morgan Stanley dropped their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, August 7th. Zacks Investment Research raised MacroGenics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research note on Friday, August 4th. Finally, ValuEngine downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $30.30.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with's FREE daily email newsletter.